GlassScriptPhysician profile
Carmen Josefa Perez
NPI 1811950140
$12,710.08
in general payments reported to CMS, 2019-2025
47 companies · $946 in 2025
The $946 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2020: $1,630 · 2021: $2,634 · 2022: $2,466 · 2023: $2,199 · 2024: $1,175 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,319.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,244.99 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,033.69 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $1,016.28 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $920.26 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $735.80 | 2019-2024 | |
| Lilly USA, LLC | $730.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $576.73 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $546.93 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.85 | 2019-2025 | Jardiance, Trijardy Xr, Glyxambi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $483.97 | 2019-2025 | Xifaxan, Cycloset, Trulance |
| Amgen INC. | $464.02 | 2019-2024 | Otezla, Repatha, Prolia |
| Paratek Pharmaceuticals, INC. | $410.76 | 2020-2023 | Nuzyra |
| Amarin Pharma, INC. | $406.88 | 2019-2022 | |
| Abbott Laboratories | $310.31 | 2020-2024 | Freestyle Libre 3 |
| Pfizer INC. | $283.89 | 2019-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.